title: Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.
abstract: Antistreptokinase antibodies present in patients as a result of previous streptococcal infections might theoretically influence the thrombolytic response to streptokinase or anistreplase. The potential influence of antibody, measured as antigen binding to immunoglobulin G, was investigated in a randomized, double-blind, multicenter patency comparison of intravenous streptokinase (1.5 million units/60 minutes) and intravenous anistreplase (30 units/2 to 5 minutes) in patients with acute myocardial infarction. Antibody results were evaluated in 333 patients (from a total study population of 370 patients) less than 76 years of age with ECG evidence of ST segment elevation who could be treated within 4 hours of the onset of symptoms. Variations in pretreatment circulating levels of antibody did not influence angiographically defined early coronary patency rates (Thrombolysis in Myocardial Infarction grade 2 or 3 perfusion, measured at a mean of 140 minutes after therapy was begun) for either streptokinase or anistreplase. Similarly the lytic response represented by systemic plasminogen activation and measured as changes in plasma plasminogen and fibrinogen levels after dosing (at mean times of 90 minutes and 24 hours) was not correlated with baseline antibody levels. Furthermore, pretreatment antibody was not a risk factor for poor outcome in response to streptokinase or anistreplase (reocclusion within 24 hours, in-hospital death, or stroke) and did not correlate with hypotension or allergic-type reactions recorded as adverse events. In conclusion, within the population limits defined by the inclusion and exclusion criteria of the study (patients were excluded if they had received streptokinase or anistreplase within the previous 6 months), pretreatment antistreptokinase immunoglobulin G is not a significant determinant of the efficacy response to streptokinase or anistreplase.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Epsom, Surrey, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Fears
authors.forename: J
authors.initials: J
authors.lastname: Hearn
authors.forename: R
authors.initials: R
authors.lastname: Standring
authors.forename: J L
authors.initials: JL
authors.lastname: Anderson
authors.forename: V J
authors.initials: VJ
authors.lastname: Marder
mesh_terms: D016255:Anistreplase / Q000627:therapeutic use*; D003331:Coronary Vessels / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D013300:Streptokinase / Q000276:immunology* / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D007074:Immunoglobulin G; D016255:Anistreplase; D013300:Streptokinase